Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PELICAN-IPC: pembrolizumab plus neoadjuvant EC-paclitaxel in HER2-negative inflammatory breast cancer
2024-514899-41-00Phase 2Authorised
- Sponsor
- Institut Paoli-Calmettes
- Start
- Oct 2024
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of pembrolizumab, cyclophosphamide, epirubicin and paclitaxel in inflammatory breast cancer (IBC) and breast cancer (2 arms), sponsored by Institut Paoli-Calmettes. Primary endpoints: Central pathological complete response rate and Dose-limiting toxicity rate. Planned start Oct 2024; status: authorised.
02
Drugs
03
Conditions
inflammatory breast cancer (IBC)breast cancer
Beyond the preview
Go deeper on 2024-514899-41-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514899-41-00.